Navigation Links
Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
Date:1/8/2014

BURLINGTON, Mass., Jan. 8, 2014 /PRNewswire/ -- Flexion Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock.  All of the shares to be sold in the offering will be offered by Flexion. The number of shares to be offered and the price range for the offering have not yet been determined.

BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com; or from Wells Fargo Securities, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, Telephone: (800) 326-5897, Email: cmclientsupport@wellsfargo.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. The company is currently advancing a portfolio of drug candidates that together have the potential to treat pain from mild, moderate and severe forms of osteoarthritis. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe osteoarthritis pain. The company is developing two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage osteoarthritis patients.

 


'/>"/>
SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
2. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
3. Flexion Therapeutics Secures $20 Million in Series B Financing
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets ... Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End ... Forecasts to 2021" report to their offering. ... , , ... Million in 2021 from USD 574.8 Million in 2016, growing at ...
(Date:12/5/2016)... December 5, 2016 According to a new report published ... Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the global ... reach $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 ... four-fifths share. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... ... , ... While James Earl Jones is known for myriad roles on stage ... "Front Page". One of the forthcoming episodes examines mammogram techniques; a very important part ... part due to early detection. Like any other disease, treatments have a much higher ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
Breaking Medicine News(10 mins):